PCRX-201A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Sponsor:

Pacira Pharmaceuticals, Inc

Code:

NCT06884865

Conditions

Osteoarthritis (OA) of the Knee

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Interventions

Enekinragene Inzadenovec (PCRX-201)

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is.

Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time.

Participants will be asked to

Visit the clinic for pretreatment and drug administration
Visit the clinic for checkups and tests:

1. Screening through Week 52: intially weekly, bi-weekly, later monthly
2. Week 53 through Week 260 (Year 5): 8 visits throughout the period

Conditions

Osteoarthritis (OA) of the Knee

Study ID

NCT06884865

Start date

Feb 26, 2025

Status verified date

Aug, 2026

Completion date

Jul, 2032

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions.
Subjects must be male or female and 45 to 80 years old, inclusive, at Screening.
Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable).
Subjects must have index knee pain for >15 days over the last month before Screening (subject self-reporting is acceptable).
Subjects must have received 2 or more failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, "structured land-based exercise" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months.
Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening.
Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline.
Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline.
Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study
Subjects must have active synovitis in the index knee as determined by ultrasound Doppler (Part A only) For Part B, participants must have active synovitis in the index knee as determined by contrast-enhanced MRI.
Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:

1. Knee pain
2. At least 1 of the following:

i. Age >50 years ii. Morning stiffness <30 minutes iii. Crepitus on knee motion c. Osteophytes

Subjects must have K-L Grade 2, 3, or 4 (Part A) or K-L Grade 2 or 3 (Part B) in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment
Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI (Part A). For Part B, participants need to show the presence of synovitis ≥5 on the Guermazi synovitis scoring scale using contrast-enhanced MRI to be enrolled.

Exclusion Criteria:

Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.
Subjects have any active systemic or local infection, including infection of the index knee
Subjects are unable to undergo MRI with contrast MRI
Subjects with X-ray or MRI exclusionary events
Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening
Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)
Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years
Subjects have used IA steroids ≤3 months before screening
For Part B, subjects with any surgery related tot he index knee.

Other protocol-defined criteria apply

Study Design

Enrollment

135 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment